Qinghai Chenfei Pharmaceutical Co. Ltd.

Primary objective: To observe the pharmacokinetic characteristics of a single subcutaneous injection of the test preparation exenatide injection 10 μg (specification: 2.4 ml: 0.6 mg, 1 vial/box; produced and provided by Qinghai Chenfei Pharmaceutical Co., Ltd.) and the reference preparation exenatide injection 10 μg (trade name: Byetta®; specification: 0.25 mg/ml, 2.4 ml/vial; 1 vial/box; produced by Baxter Pharmaceutical Solutions LLC.; provided by Qinghai Chenfei Pharmaceutical Co., Ltd.) in healthy Chinese subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary objective: To observe the safety of the test preparation exenatide injection and the reference preparation exenatide injection (Byeetta®) in healthy Chinese subjects.